Anti-CD19 Universal CAR-T Cells injection
GC011-411
Phase 1 mab active
Quick answer
Anti-CD19 Universal CAR-T Cells injection for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Modality
- mab
- Status
- active